Aurobindo Pharma Transfers Domestic Branded Generics Business to Subsidiary

The latest update is out from Aurobindo Pharma Ltd ( (IN:AUROPHARMA) ).

Aurobindo Pharma’s board has approved the transfer of its domestic branded generic pharmaceutical formulations business to its wholly owned subsidiary, Auropharm Limited, via a Business Transfer Agreement. The move aligns with the company’s strategy to streamline and accelerate its domestic operations for faster growth.

The business, which contributed 0.55% of consolidated turnover and 0.45% of consolidated net worth in the last financial year, will be transferred on a going-concern basis for a lump-sum consideration of INR 143.21 crore. Subject to customary conditions, the transaction is expected to close within 90–120 days, with economic benefits accruing to Auropharm from April 1, 2026, further consolidating the group’s branded generics trade within a focused subsidiary.

More about Aurobindo Pharma Ltd

Aurobindo Pharma Ltd is an India-based pharmaceutical company focused on generic medicines and formulations, with a presence in domestic and international markets. The company operates across multiple therapeutic segments, supplying branded and non-branded generic pharmaceutical products and related formulations.

Average Trading Volume: 99,194

Technical Sentiment Signal: Strong Buy

Current Market Cap: 775.9B INR

See more insights into AUROPHARMA stock on TipRanks’ Stock Analysis page.